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Purpose: To assess the intraocular pressure (IOP)-lowering effects of bimatoprost
sustained-release implant (BimSR) in normotensive monkeys receiving topical
bimatoprost.
Methods: Six eyes from six female, normotensive, cynomolgus monkeys were treated
with once-daily topical latanoprost 0.005% plus twice-daily fixed-combination
dorzolamide 2%/timolol 0.5%. At week 5, topical latanoprost was switched to once-
daily topical bimatoprost 0.03% and twice-daily dorzolamide 2%/timolol 0.5% was
continued. At week 8, BimSR 20 lg was administered intracamerally to three eyes and
topical therapy was continued in all eyes. At week 12, all topical therapy was
discontinued and animals were monitored for another 4 weeks. IOP was measured
with a TonoVet rebound tonometer in nonsedated animals weekly for 16 weeks.
Results: Average mean (standard deviation) IOP was 19.8 (1.6) mm Hg at baseline,
15.7 (0.9) mm Hg during treatment with topical latanoprost/dorzolamide/timolol from
weeks 1 to 5, and 14.2 (0.5) mm Hg during weeks 6 to 8 after topical latanoprost was
switched to topical bimatoprost. After BimSR was added, average mean IOP during
weeks 9 to 12 was 10.8 (1.3) mm Hg, a decrease of 3.9 mm Hg compared with the
topical-only arm. When topical therapy was discontinued, IOP in BimSR-treated eyes
remained below that in unmedicated eyes (15.8 [0.9] vs. 20.2 [0.2] mm Hg at weeks
14–16).
Conclusions: Intracameral BimSR has IOP-lowering effects additive to those of topical
bimatoprost, suggesting an additional mechanism of action with intracameral drug
delivery.
Translational Relevance: Compared with topical bimatoprost, intracameral BimSR
may have an additional mechanism of action of IOP lowering.
Introduction
Topical medical therapy with prostaglandin analogs
(PGAs) is the most common first-line treatment for
primary open-angle glaucoma.1 Topical PGAs primar-
ily enhance uveoscleral outflow and also increase
trabecular outflow facility.2–4 Although substantial,
intraocular pressure (IOP) lowering with PGAs reaches
a ceiling due to unknown mechanisms beyond which
IOP cannot be lowered any more by increasing the
dose. In fact, increasing the dose of topical bimato-
prost or latanoprost from once- to twice-daily dosing
results in a significant decrease in overall IOP-lowering
efficacy.5–8
Bimatoprost sustained-release intracameral im-
plant (bimatoprost SR) is a biodegradable polymer
drug delivery system designed to slowly release
bimatoprost into the anterior chamber over a period
of 4 to 6 months, while the matrix slowly degrades to
inert compounds (Fig. 1).9 In a preclinical dose-
ranging study, the IOP-lowering efficacy of several
doses of bimatoprost SR (8–120 lg) was compared
with that of topical bimatoprost 0.03% in ocular
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normotensive beagle dogs (data on file; Allergan plc,
Dublin, Ireland). The magnitude of IOP reduction
increased with increasing bimatoprost SR dose
throughout the range tested. Moreover, the IOP
lowering with bimatoprost SR doses of 60 lg
exceeded that produced by topical bimatoprost
0.03%, the topical dose that achieves maximal
lowering of IOP. This suggested that there may be
mechanistic differences between topically and intra-
camerally administered bimatoprost.
Based on the differences in IOP lowering seen with
topical and intracameral dosing of bimatoprost, a
difference is hypothesized in the mechanisms of action
for each route of administration. If intracameral
dosing introduces an additional mechanism of action
compared with topical dosing, one can also hypoth-
esize that the combination of intracamerally and
topically dosed bimatoprost should achieve an IOP
reduction greater than topical dosing alone. We tested
the hypothesis that intracameral bimatoprost, deliv-
ered with bimatoprost SR, produces additional IOP
lowering when added to a topical regimen.
Methods
This study was performed at Allergan plc under an
approved Animal Care and Use Committee protocol.
All procedures were in compliance with Animal
Welfare Act Regulations (9 CFR 3) and routine
veterinary care was performed in accordance with the
Animal Welfare Act, the Guide for the Care and Use
of Laboratory Animals, the Office of Laboratory
Animal Welfare, and the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research.
Six female, normotensive, drug-naı¨ve cynomolgus
monkeys weighing 2.6 to 3.2 kg were studied. To
reduce the chance that the IOP measurements could
be confounded by the effects of anesthesia, all animals
were chair-trained for awake IOP examinations for 3
months before the study so that IOP measurements
could be performed without topical or general
anesthesia.
The left eye was designated as the study eye. In all
animals, the study eye was treated with topical
latanoprost 0.005% (Xalatan; Pfizer Inc., New York,
NY) once daily plus topical fixed-combination
dorzolamide 2%/timolol 0.5% (Cosopt; Merck &
Co., Kenilworth, NJ) twice daily for 5 weeks (Fig.
2). A multiple-drug topical regimen of PGA, carbonic
anhydrase inhibitor, and beta-blocker frequently is
used in glaucoma patients as a maximal tolerated
medical therapy10 and was used in the animals in an
attempt to reduce IOP as much as possible by
maximally increasing aqueous outflow and decreasing
aqueous production. To assess the differences in
efficacy between monkey and humans, at week 5 after
IOP was measured, topical latanoprost was switched
to topical bimatoprost 0.03% (Lumigan; Allergan plc)
once daily while dorzolamide/timolol twice daily was
continued. An additional 1 mm Hg of mean IOP
lowering was observed 1 week later (Table 1),
confirming that topical bimatoprost exhibited a
similar difference in efficacy compared with latano-
prost as when used in humans, which increases
confidence in the translatability of the study results.
The animals were continued on the regimen of topical
bimatoprost plus dorzolamide/timolol. All doses of
topical latanoprost and bimatoprost were given 5
minutes after the evening dose of dorzolamide/timolol.
Topical therapy was continued in all eyes through
week 12, when the topical therapy was discontinued in
all eyes after IOP measurement. The animals then
were monitored for an additional 4 weeks.
At week 8, bimatoprost SR 20 lg was administered
to the study eyes of three animals following the IOP
measurement. Before dosing with bimatoprost SR,
each animal was sedated with intramuscular ketamine
(15 mg/kg) and atropine (0.022 mg/kg) and the eye
was anesthetized with topical proparacaine hydro-
chloride 0.5%. Povidone iodine 5% drops were
applied preoperatively for 2 minutes and the eye
Figure 1. Bimatoprost SR includes (A) a single-use applicator
system and (B) a biodegradable micro-implant containing
bimatoprost.
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Figure 2. Study design. BID, twice daily; BimSR, bimatoprost sustained-release implant (bimatoprost SR); FC, fixed-combination; QD,
once daily.
Table 1. Mean IOP (6 SEM) at Key Time Points, mm Hg
Time and Treatment
All Animals,
n ¼ 6
BimSR Added to
Topical Triple Therapy,
n ¼ 3
No Implant Added to
Topical Triple Therapy,
n ¼ 3
Baseline: before any treatment 19.8 6 0.7 — —
Week 1: 1 week after initiating topical
dorzolamide/timolol/latanoprost triple
therapy
15.8 6 1.0* — —
Week 6: 1 week after switch to topical
dorzolamide/timolol/bimatoprost triple
therapy
14.8 6 1.1* — —
Week 9: 1 week after addition of BimSR or
no implant to topical dorzolamide/
timolol/bimatoprost triple therapy
— 11.0 6 0.5*,† 14.5 6 1.3*
Week 12: 4 weeks after addition of BimSR
or no implant to topical dorzolamide/
timolol/bimatoprost triple therapy
— 9.5 6 0.6*,† 14.5 6 1.8*
Week 16: 4 weeks after all topical therapy
stopped
— 16.5 6 1.3*,† 20.0 6 1.5
BimSR, bimatoprost sustained-release implant (bimatoprost SR).
* P , 0.005 vs. baseline,
† P  0.012 vs. no implant added to topical triple therapy.
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was rinsed with balanced salt solution. A lid speculum
was placed and the eye was visualized through an
operating microscope. Bimatoprost SR was inserted
into the anterior chamber using a single-use applica-
tor equipped with a 27-gauge needle. The needle was
introduced just anterior to the insertion of the
conjunctiva at the limbus through the clear cornea
in the superotemporal quadrant using countertraction
with a tooth forceps lightly grasping the conjunctiva
near the limbus. Topical gatifloxacin 0.3% eye drops
were placed in the eye postoperatively.
A TonoVet veterinary rebound tonometer (Icare
USA, Raleigh, NC) was used to measure IOP on calm
(pole and collar handling system), fully conscious,
nonsedated animals. The IOP was measured at the
same time of day throughout the study (10 AM 6 1
hour). The baseline IOP measurement was taken on
the day before topical dosing was initiated, and after
initiation of topical dosing, IOP was measured every 7
days through week 16. The morning dose of
dorzolamide/timolol was administered at 8 AM 6 1
hour, and IOP was measured 2 hours later (peak
effect).
A mixed-model repeated-measures method was
used for statistical analysis: IOP was the response
variable, and the dose group (topical therapy only or
topical therapy þ bimatoprost SR), time, and dose
group by time interaction were treated as fixed effects.
The data were fitted to the model, and comparisons
with baseline and between dose groups were made
based on the fitted model. All comparisons reported
were from the same model; no adjustment was made
for multiple comparisons due to the small sample size.
Results
Table 1 shows mean values of IOP observed at key
time points in the study, and Table 2 shows estimates
of IOP changes from baseline at each postbaseline
time point in the repeated-measures mixed-effects
model. Mean (6 standard deviation) baseline IOP
was 19.8 6 1.6 mm Hg, and during treatment with
Table 2. Estimates of IOP Changes From Baseline in the Mixed-Model Repeated-Measures Analysis, mm Hg
Treatment Week
Estimate of IOP Change
From Baseline
Limits of
95% Confidence Interval
Topical dorz/tim þ lat, n ¼ 6 1 4.06 5.26, 2.85
Topical dorz/tim þ lat, n ¼ 6 2 5.14 6.34, 3.94
Topical dorz/tim þ lat, n ¼ 6 3 4.06 5.26, 2.85
Topical dorz/tim þ lat, n ¼ 6 4 4.72 5.93, 3.52
Topical dorz/tim þ lat, n ¼ 6 5 2.64 3.84, 1.44
Topical dorz/tim þ bim, n ¼ 6 6 4.97 6.18, 3.77
Topical dorz/tim þ bim, n ¼ 6 7 5.97 7.18, 4.77
Topical dorz/tim þ bim, n ¼ 6 8 5.72 6.93, 4.52
Bimatoprost SR administered at week 8 after IOP measurement
Topical dorz/tim þ bim, n ¼ 3 9 8.79 10.52, 7.05
Topical dorz/tim þ bim, n ¼ 3 10 7.29 9.02, 5.55
Topical dorz/tim þ bim, n ¼ 3 11 9.45 11.19, 7.71
Topical dorz/tim þ bim, n ¼ 3 12 10.29 12.02, 8.55
No topical therapy, n ¼ 3 14 4.62 6.36, 2.88
No topical therapy, n ¼ 3 16 3.29 5.02, 1.55
No Bimatoprost SR at week 8
Topical dorz/tim þ bim, n ¼ 3 9 5.33 7.07, 3.59
Topical dorz/tim þ bim, n ¼ 3 10 4.99 6.73, 3.25
Topical dorz/tim þ bim, n ¼ 3 11 4.83 6.57, 3.09
Topical dorz/tim þ bim, n ¼ 3 12 5.33 7.07, 3.59
No topical therapy, n ¼ 3 14 þ0.51 1.23, þ2.25
No topical therapy, n ¼ 3 16 þ0.17 1.57, þ1.91
Bim, bimatoprost 0.03% once daily; Bimatoprost SR, bimatoprost sustained-release implant 20 lg; dorz/tim, fixed-
combination dorzolamide 2%/timolol 0.5% twice daily; lat, latanoprost 0.005% once daily.
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topical latanoprost/dorzolamide/timolol therapy
from weeks 1 to 5, the average mean IOP was 15.7
6 0.9 mm Hg (P , 0.005 vs. baseline at all time
points; Fig. 3). When latanoprost in the triple
combination topical therapy was switched to bimato-
prost at week 5, there was an additional decrease in
average mean IOP to 14.2 6 0.5 mm Hg (P , 0.0001
vs. baseline at all time points) through week 8. The
average mean IOP reduction of the topical combina-
tion with bimatoprost (weeks 6–8) was 1.4 mm Hg
greater than with latanoprost (weeks 1–5; P¼ 0.0185).
When bimatoprost SR was added to this triple
combination in half of the monkeys (n ¼ 3), there
was an additional, statistically significant decrease in
average mean IOP during weeks 9–12 to 10.8 6 1.3
mm Hg (P  0.01 vs. topical alone at weeks 9, 11, and
12), which was an additional decrease of 3.9 mm Hg
compared to the topical-only group. When topical
therapy was discontinued, IOP increased, but the IOP
in eyes treated with bimatoprost SR remained below
that in unmedicated eyes at weeks 14 (P¼ 0.0002) and
16 (P ¼ 0.0117).
No intraoperative or postoperative complications
of bimatoprost SR administration were observed. In
addition, no adverse effects were documented in eye
examinations performed before the IOP measure-
ments.
Discussion
This was the first study to evaluate the additive
IOP-lowering effects of bimatoprost SR with topical
IOP-lowering medications. The results showed that
addition of intracameral bimatoprost SR provided
further IOP lowering in monkeys already receiving
topically administered bimatoprost 0.03% once daily.
Figure 3. Effect of bimatoprost SR and topical ocular hypotensive therapy on mean IOP in normotensive monkeys. Topical therapy
consisted of dorzolamide 2%/timolol 0.5% twice daily plus latanoprost once daily in the evening (weeks 0–5) or dorzolamide 2%/timolol
0.5% twice daily plus bimatoprost once daily in the evening (weeks 5–12). IOP was measured 2 hours after morning topical dosing, at
peak effect. IOP values shown are mean 6 SEM.
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A previous study in cynomolgus monkeys demonstrat-
ed that the clinical dose of topical bimatoprost (9 lg,
the dose in a 30 lL drop of bimatoprost 0.03%)
reduces IOP at least as effectively as a dose 3 times
higher (27 lg), and administering the clinical dose of
topical bimatoprost twice daily results in less IOP
lowering than once-daily dosing.11 This suggests that in
monkeys, as in humans,5,6,12 once-daily administration
of the bimatoprost 0.03% formulation produces the
maximal IOP lowering achievable with topical bima-
toprost administration. Thus, the additional IOP
lowering produced by bimatoprost SR in monkeys
treated with once-daily topical bimatoprost 0.03%
suggests that intracameral PGA dosing may have an
additional mechanism of action for IOP lowering
beyond the expected increases in uveoscleral outflow
and possibly outflow facility. Since the eyes were on
two potent aqueous humor production suppressants
(i.e., dorzolamide/timolol), the additional mechanism
of action was not likely due to additional aqueous
production suppression.
An unpublished study in beagle dogs showed that
the IOP lowering produced by bimatoprost SR is
dose-dependent and at higher doses exceeds that
produced by topical bimatoprost administration
(Allergan plc; data on file). Similarly, in a phase 1/2
study in human subjects with glaucoma, intracameral
administration of bimatoprost with bimatoprost SR
produced dose-dependent IOP lowering. Moreover, at
the higher dose strengths of the implant, the mean
IOP reduction at early time points in study eyes was
incrementally greater than the mean IOP reduction in
fellow eyes treated with once-daily topical bimato-
prost 0.03%.9 These findings also are consistent with
the hypothesis that intracameral delivery of bimato-
prost with bimatoprost SR has an additional mech-
anism of IOP lowering compared with topical dosing.
The 20-lg dose strength of bimatoprost SR used in
this study in monkeys was the same as the highest
dose strength of bimatoprost used in the phase 1/2
clinical trial.9 Reported interim results of the clinical
study showed that a single administration of implant
controlled IOP in 71% of patients with glaucoma for
up to 6 months.9 Consistent with the clinical findings,
in our study significant IOP lowering was produced
by the implant throughout the follow-up period (up
to 8 weeks after administration). From weeks 8–12,
bimatoprost SR reduced the IOP in eyes already
treated with topical timolol/dorzolamide/bimato-
prost, and after the topical regimen was stopped at
week 12, bimatoprost SR continued to reduce IOP
relative to the baseline IOP through week 16.
A possible explanation for the additional IOP
lowering produced by bimatoprost SR when added to
a topical regimen including bimatoprost is that the
implant produces much higher concentrations of bima-
toprost in the target tissues within the eye than is possible
with topical dosing, as has been demonstrated in a study
in dogs,13 and these higher concentrationsmay be able to
enhance uveoscleral outflow and/or outflow facility. The
ability of a topically applied drug to reach the intraocular
tissues controlling aqueous outflow is limited by its
ability to penetrate the cornea or conjunctiva/sclera.
Intracameral drug delivery removes these barriers to
drug penetration to intraocular target tissues. This
explanation does not seem consistent with the inability
of higher topical concentrations of bimatoprost to
improve IOP lowering, since increasing the concentra-
tion of bimatoprost applied topically also would be
expected to increase intraocular drug concentrations.
However, the reasons for the ceiling effect for IOP
lowering with increased concentrations of topical PGAs
are not well understood, and it remains possible that the
location or kinetics of drug delivery with the implant, or
the very high drug concentrations achieved at target
tissues after intracameral administration, results in
enhancement of uveoscleral outflow and/or outflow
facility and improved IOP lowering.
A second possible explanation for the additive IOP
lowering produced by bimatoprost SR in monkeys
treated with topical medications is that its mechanism
of IOP lowering involves a decrease in episcleral
venous pressure (EVP), as well as an increase in
uveoscleral outflow and outflow facility. This possi-
bility was suggested by a previous study in dogs that
showed that intracameral delivery of bimatoprost SR
led to a significant, sustained decrease in EVP
following a transient increase in EVP.14 In contrast,
no decrease in EVP occurred in dogs after topical
administration of latanoprost15 or bimatoprost (Al-
lergan plc, data on file). Preclinical studies of IOP
regulation in dogs and monkeys provide useful
information relevant to human physiology, because
the anatomy and function of aqueous outflow systems
are similar in humans, monkeys, and dogs.16 Dogs
have a venous plexus instead of a true Schlemm’s
canal, but aqueous collector vessels are found in dogs,
humans, and monkeys.16 The flow of aqueous from
the collector vessels into the episcleral vasculature,
and consequently the IOP, is influenced by the
EVP.17,18 EVP can be measured invasively by
cannulation of the episcleral vein or noninvasively
using a pressure chamber (episcleral venomanometer)
that measures the pressure required to constrict the
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vein to a predetermined endpoint.19 In animal studies,
these methods produce comparable measurements of
EVP.19 Regardless of the method used for EVP
measurement, EVP has been reported to be similar
across species. EVP measured with a venomanometer
has been reported to be approximately 10 mm Hg in
normotensive beagle dogs14 and ranged from approx-
imately 8 to 11 mm Hg in normal human subjects.18 It
is not possible to measure EVP noninvasively in
cynomolgus monkeys, because dense perilimbal pig-
mentation just 4 to 6 mm from the limbus impedes
visualization of the episcleral outflow vessels (Fig. 4),
and the anatomy of the eye, deeply inset in the tight
orbit, prevents applanation of the episcleral vessels
with the commercially available venomanometer.
However, mean EVP measured in cynomolgus
monkeys by direct cannulation was reported to be
10.4 mm Hg,20 similar to the EVP measured
noninvasively in humans and dogs.
We chose to do the study in cynomolgus monkeys
because of the close relationship of the species to
humans. Monkey eyes are similar to human eyes in
most respects, and importantly, topical medications
used to lower IOP in humans with glaucoma have
similar effects on aqueous dynamics and demonstrate
similar IOP-lowering effects in monkeys. Furthermore,
topical PGAs have been shown to produce similar
percentage IOP reductions in normotensive monkey
eyes as in laser-induced ocular hypertensive monkey
eyes.21,22 We also have observed a low-grade chronic
anterior uveitis in the laser-induced ocular hypertensive
monkey eye model (Tsai S, et al. IOVS. 2011;52:
ARVO E-Abstract 2435), and the degree to which this
could confound the IOP measurements in this implant
study was not known. Therefore, normotensive mon-
keys were used in this study as a more appropriate
model to evaluate drug effects on IOP that are
translatable to human eyes with glaucoma.
In conclusion, our study results suggest that
bimatoprost SR may have an additional IOP-lower-
ing mechanism of action that differentiates it from
topical PGAs. This incremental additional IOP
lowering may be related to EVP reduction, but other
explanations are possible. Additional mechanism of
action studies are needed to further explore reasons
for differential effects of topically and intracamerally
administered bimatoprost in animals and humans.
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